Xerion Pharmaceuticals is a functional proteomics company that applies its proprietary technologies for identifying targets that play a functional role in a disease process and developing novel human antibody therapeutics to treat progressive cancers. Xerion’s technology platforms consists of three areas such as Xcelerate™, a simultaneous high throughput protein identification by mass spectrometry and combinatorial screening of corresponding ligands, XCALibur™, a proprietary target validation technology by ‘protein knockout’ and X-plore™, which identifies functional sites or epitopes on proteins.